The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
Blackstone, a private investment firm, has closed on its first fund in the life sciences, Blackstone Life Sciences, with $4.6 billion in total capital commitments.
The fund is focused on three main investment strategies: strategic collaborations...
More than 20 biopharmaceutical companies have announced their participation in the AMR Action Fund to support research of new antibiotics to address the rise of antibiotic-resistant infections, also called antimicrobial resistance (AMR), with a...
Sanofi and Kymera Therapeutics, a Cambridge, Massachusetts-based biopharmaceutical company, have entered into a multi-program strategic collaboration to develop and commercialize protein-degrader therapies for immune-inflammatory diseases, in a...
Sanofi and Kiadis Pharma, an Amsterdam-based clinical-stage company developing therapeutics based on natural killer (NK) cells, have entered into an exclusive license agreement, in a deal worth up to EUR 875 ($996 million), for developing select...
The US Food and Drug Administration (FDA) is working toward resuming onsite domestic inspections in the US beginning the week of July 20, 2020, with a new risk-assessment rating system to determine when and where it is safest to conduct prioritized...
Gilead Sciences has announced plans to invest EUR 7 million ($8 million) to expand its operations in Ireland with the opening a new base in Dublin, the establishment a pediatric center of excellence in Ireland, and the addition of 140 new...
Gilead Sciences and Arcus Biosciences, a Hayward, California clinical-stage company focused on cancer immunotherapies, have closed their deal for a 10-year partnership, worth up to $2 billion, to co-develop and co-commercialize Arcus' therapeutic...
Amgen has made an additional investment of $421 million in BeiGene, a Beijing-based pharmaceutical company, which builds on a $2.8-billion drug-development and commercialization pact that the companies finalized earlier this year (2020).
In...
The latest on manufacturing and potential treatments for COVID-19 from Moderna, Pfizer, Gilead, Novartis, AstraZeneca, Emergent BioSolutions, CSL Behring, and Biocon.
Moderna To Begin Phase III Trials for COVID-19 Vaccine Moderna, a clinical-stage...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has established a new clinical trials network that aims to enroll thousands of volunteers in large-scale clinical trials to test a...
A federal appeals courts has ruled in favor of Amgen regarding a patent-infringement suit with Novartis’ Sandoz over Amgen’s Enbrel (etanercept), one of Amgen’s top-selling drugs with 2019 global sales of $5.2 billion. The court ruling keeps Sandoz...
A roundup of news from China (Boehringer Ingelheim), Europe (J&J), and the US (Lupin, Merck & Co., Sandoz, Civica Rx, and Mylan).
China
Boehringer Ingelheim Launches External Innovation Hub in ChinaBoehringer Ingelheim (BI) is launching...
Regeneron Pharmaceuticals, a Tarrytown, New York-based biopharmaceutical company, has been awarded a $450-million contract from the US government to manufacture and supply REGN-COV2, Regeneron's investigational double antibody cocktail that is...
The latest on manufacturing and potential treatments for COVID-19 with news from Sanofi, Mylan, GSK, Moderna, CSL Behring, CureVac, Sinovac, Zydus Cadila, and the WHO.
News from Sanofi, Mylan, GSK, Moderna, CSL Behring
Sanofi, Regeneron End US...
Merck & Co. and Foghorn Therapeutics, a Cambridge, Massachusetts-based gene-therapy company, have formed a strategic collaboration, in a deal worth up to $425 million, to discover and develop therapeutics against a transcription factor target...
